CN106413736A - 晶型 - Google Patents

晶型 Download PDF

Info

Publication number
CN106413736A
CN106413736A CN201580029787.7A CN201580029787A CN106413736A CN 106413736 A CN106413736 A CN 106413736A CN 201580029787 A CN201580029787 A CN 201580029787A CN 106413736 A CN106413736 A CN 106413736A
Authority
CN
China
Prior art keywords
pure
crystalline form
compound
pxrd
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580029787.7A
Other languages
English (en)
Chinese (zh)
Inventor
S.陈
B.D.加特斯
A.Y.舍克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CN106413736A publication Critical patent/CN106413736A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201580029787.7A 2014-06-06 2015-06-05 晶型 Pending CN106413736A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462008786P 2014-06-06 2014-06-06
US62/008786 2014-06-06
PCT/US2015/034371 WO2015188045A1 (en) 2014-06-06 2015-06-05 Crystal forms

Publications (1)

Publication Number Publication Date
CN106413736A true CN106413736A (zh) 2017-02-15

Family

ID=54767417

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580029787.7A Pending CN106413736A (zh) 2014-06-06 2015-06-05 晶型

Country Status (8)

Country Link
US (2) US9321807B2 (enExample)
EP (2) EP3151850A4 (enExample)
JP (4) JP2017518319A (enExample)
CN (1) CN106413736A (enExample)
AU (2) AU2015269306B2 (enExample)
CA (1) CA2948902C (enExample)
MX (1) MX373056B (enExample)
WO (1) WO2015188045A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3151850A4 (en) * 2014-06-06 2017-11-29 AbbVie Inc. Crystal forms
WO2021137256A1 (en) 2020-01-03 2021-07-08 Mylan Laboratories Limited Polymorphic forms of glecaprevir
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025849A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis c virus
CN103209703A (zh) * 2010-09-21 2013-07-17 益安药业 大环脯氨酸衍生的hcv丝氨酸蛋白酶抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604234A (en) * 1991-09-05 1997-02-18 Abbott Laboratories Substituted thiol macrolactam immunomodulators
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
KR100995390B1 (ko) * 2006-01-02 2010-11-19 주식회사 삼양제넥스 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법
EP2540349B1 (en) * 2008-07-22 2014-02-12 Merck Sharp & Dohme Corp. Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor
MX2014001944A (es) * 2011-08-19 2014-03-27 Merck Sharp & Dohme Formas cristalinas de un inhibidor de la proteasa del virus de la hepatitis c.
JP6573550B2 (ja) * 2012-07-12 2019-09-11 アッヴィ・アイルランド・アンリミテッド・カンパニー Ｈｃｖ阻害剤の結晶形
WO2015061742A2 (en) * 2013-10-25 2015-04-30 Abbvie, Inc. Methods for treating hcv
EP3151850A4 (en) * 2014-06-06 2017-11-29 AbbVie Inc. Crystal forms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025849A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis c virus
CN103209703A (zh) * 2010-09-21 2013-07-17 益安药业 大环脯氨酸衍生的hcv丝氨酸蛋白酶抑制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张鹏等: "药物多晶型研究进展", 《海峡药学》 *
罗永明等: "《中药化学》", 30 September 2013, 西安交通大学出版社 *

Also Published As

Publication number Publication date
CA2948902A1 (en) 2015-12-10
JP2017518319A (ja) 2017-07-06
AU2015269306A1 (en) 2016-12-22
US20160220487A1 (en) 2016-08-04
AU2020239679A1 (en) 2020-10-15
JP2025004239A (ja) 2025-01-14
JP2023089125A (ja) 2023-06-27
AU2015269306B2 (en) 2020-06-25
EP3151850A4 (en) 2017-11-29
EP4403223A2 (en) 2024-07-24
WO2015188045A1 (en) 2015-12-10
JP2021113192A (ja) 2021-08-05
MX2016016127A (es) 2017-02-23
US9561181B2 (en) 2017-02-07
EP3151850A1 (en) 2017-04-12
US9321807B2 (en) 2016-04-26
MX373056B (es) 2020-05-20
US20150353600A1 (en) 2015-12-10
EP4403223A3 (en) 2024-10-09
CA2948902C (en) 2022-11-22

Similar Documents

Publication Publication Date Title
JP2025004239A (ja) 結晶形
JP2018070631A (ja) Ｈｃｖ阻害剤の結晶形
JP2022133438A (ja) 結晶形
HK40114208A (en) Crystal forms
US20150175612A1 (en) Crystal forms
US20190202812A1 (en) Crystal Forms
HK40098358A (en) Crystal forms
BR112016027366B1 (pt) Processo para preparar uma composição farmacêutica que compreende um composto que é um potente inibidor da protease do vírus da hepatite c

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170215

RJ01 Rejection of invention patent application after publication